Sugi Predict

Sugi Predict / Compounds / SCHEMBL19253531

SCHEMBL19253531

SCHEMBL19253531

CCOC(=O)c1nn2cc(-c3cnn(C)c3)nc(O)c2c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ CHEK1 O14757 1/20 0.37
▸ JAK2 O60674 5/20 0.37
▸ JAK1 P23458 5/20 0.37
▸ TYK2 P29597 5/20 0.37
▸ JAK3 P52333 5/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ FGFR1 P11362 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ FGFR4 P22455 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ NPC1 O15118 7/20 0.35
▸ RAB9A P51151 5/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19253477 0.85 CHEK1 (0.46) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL17801193 0.78 JAK2 (0.41) ADORA3CHEK1JAK2JAK1TYK2
SCHEMBL21872223 0.76 CHEK1 (0.41) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL24438250 0.71 JAK2 (0.43) ADORA3JAK2JAK1TYK2JAK3
SCHEMBL19253538 0.71 JAK2 (0.47) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL19300145 0.70 JAK2 (0.35) CHEK1JAK2JAK1TYK2JAK3
SCHEMBL21033576 0.69 KDM4E (0.60) CHEK1NPC1RAB9AKDM4ERXFP1
SCHEMBL20307602 0.69 KDM4E (0.39) NPC1RAB9AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL26146265 0.68 PIK3CD (0.42) JAK2JAK1TYK2JAK3PIK3CD
SCHEMBL25236672 0.68 CHEK1 (0.39) ADORA3CHEK1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2022-10-18 — — US disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
EP-3712153-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2021-12-01 — — EP disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2020-12-24 — — US disclosed
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2020-11-03 — — US disclosed
EP-3419978-B1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER (US) 2020-04-15 — — EP disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2019-03-07 — — US disclosed
EP-3419978-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2019-01-02 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 ADORA3 519/4885ADORA2A 1955/4885ADORA1 900/4885
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 ADORA3 506/4885ADORA2A 1842/4885ADORA1 867/4885
US-10822341-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CCR6 ADORA3 506/4885ADORA2A 1842/4885ADORA1 867/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 ADORA3 207/4885ADORA2A 701/4885ADORA1 186/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 ADORA3 506/4885ADORA2A 1842/4885ADORA1 867/4885
US-20200399281-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CBR1 ADORA3 519/4885ADORA2A 1955/4885ADORA1 900/4885
US-20190071448-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 ADORA3 506/4885ADORA2A 1842/4885ADORA1 867/4885
US-11472809-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives SYMPK, IL15, STAT6 ADORA3 3382/4885ADORA2A 3956/4885ADORA1 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.